| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Department of Integrative Biology and Pharmacology and
Division of Immunology and Organ Transplantation, Department of Surgery, University of Texas Medical School, Houston, TX 77030; and
ISIS Pharmaceuticals, Molecular and Cellular Pharmacology, Carlsbad, CA 92008
Stat5a/b exhibits 96% homology and are required for normal immune function. The present studies examined Stat5a/b function in lymphoid cells by specific and simultaneous disruption of both proteins using novel phosphorothioate-2'-O-methoxyethyl antisense oligodeoxynucleotides (asODN). Efficient delivery was confirmed by the presence of fluorescent TAMRA-labeled ODN in 
55 and 95% in human primary and tumor cell lines, respectively. Acute asODN administration reduced levels of Stat5a (90%) in 6 h, whereas Stat5b required nearly 48 h to attain the same inhibition, suggesting that the apparent turnover rate for Stat5a was 8-fold higher than that for Stat5b. Expression of the closely related Stat3 protein was unchanged after asODN treatment, however. Molecular ablation of Stat5a/b promoted apoptotic cell death in a significant population of primary PHA-activated T cells (72%) and lymphoid tumor cell line (e.g., YT; 74%) within 24 h, as assessed by 1) visualization of karyolytic nuclear degeneration and other generalized cytoarchitectural alterations, 2) enzymatic detection of TdT-positive DNA degradation, and 3) automated cytometric detection of annexin V translocation. Contrary to findings from Stat5a/b-null mice, cell cycle progression did not appear to be significantly affected. Interestingly, IL-2-insensitive and unprimed T cells and Jurkat cells remained mostly unaffected. Finally, evidence is provided that the cytotoxicity associated with Stat5a/b ablation may derive from activation of caspase-8, an initiator protease that contributes to apoptotic cell commitment. We propose that in lymphoid cells competent to activate Stat5a and Stat5b, both proteins preferentially mediate an antiapoptotic survival influence.
This article has been cited by other articles:
|
|
 |
|
  D. K. Woo, C. R. Jones, M. N. Vanoli-Storz, S. Kohler, S. Reddy, R. Advani, R. T. Hoppe, and Y. H. Kim Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma: Characterization of Clinical Subset With Worse Outcome Arch Dermatol, June 1, 2009; 145(6): 667 - 674. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Dagvadorj, R. A. Kirken, B. Leiby, J. Karras, and M. T. Nevalainen Transcription Factor Signal Transducer and Activator of Transcription 5 Promotes Growth of Human Prostate Cancer Cells In vivo Clin. Cancer Res., March 1, 2008; 14(5): 1317 - 1324. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-H. Tan, A. Dagvadorj, F. Shen, L. Gu, Z. Liao, J. Abdulghani, Y. Zhang, E. P. Gelmann, T. Zellweger, Z. Culig, et al. Transcription Factor Stat5 Synergizes with Androgen Receptor in Prostate Cancer Cells Cancer Res., January 1, 2008; 68(1): 236 - 248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Dagvadorj, S. Collins, J.-B. Jomain, J. Abdulghani, J. Karras, T. Zellweger, H. Li, M. Nurmi, K. Alanen, T. Mirtti, et al. Autocrine Prolactin Promotes Prostate Cancer Cell Growth via Janus Kinase-2-Signal Transducer and Activator of Transcription-5a/b Signaling Pathway Endocrinology, July 1, 2007; 148(7): 3089 - 3101. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. S. Nagy, H. Rui, S. M. Stepkowski, J. Karras, and R. A. Kirken A Preferential Role for STAT5, not Constitutively Active STAT3, in Promoting Survival of a Human Lymphoid Tumor J. Immunol., October 15, 2006; 177(8): 5032 - 5040. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. A. Varker, S. V. Kondadasula, M. R. Go, G. B. Lesinski, R. Ghosh-Berkebile, A. Lehman, J. P. Monk, T. Olencki, K. Kendra, and W. E. Carson III Multiparametric Flow Cytometric Analysis of Signal Transducer and Activator of Transcription 5 Phosphorylation in Immune Cell Subsets In vitro and following Interleukin-2 Immunotherapy. Clin. Cancer Res., October 1, 2006; 12(19): 5850 - 5858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhang, R. A. Kirken, L. Furian, S. Janczewska, X. Qu, W. W. Hancock, M. Wang, N. Tejpal, R. Kerman, B. D. Kahan, et al. Allograft Rejection Requires STAT5a/b-Regulated Antiapoptotic Activity in T Cells but Not B Cells J. Immunol., January 1, 2006; 176(1): 128 - 137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Stepkowski, J. Kao, M.-E. Wang, N. Tejpal, H. Podder, L. Furian, J. Dimmock, A. Jha, U. Das, B. D. Kahan, et al. The Mannich Base NC1153 Promotes Long-Term Allograft Survival and Spares the Recipient from Multiple Toxicities J. Immunol., October 1, 2005; 175(7): 4236 - 4246. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
